ArticleJournal of translational medicine2011
Deep sequencing of gastric carcinoma reveals somatic mutations relevant to personalized medicine.
Article in Journal of translational medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Comprehensive Integration of Genome-Wide Association and Gene Expression Studies Reveals Novel Gene Signatures and Potential Therapeutic Targets forFrontiers in immunology · 2021Pooled it
- Differential networking meta-analysis of gastric cancer across Asian and American racial groups.BMC systems biology · 2018Pooled it
- The Anti-Cancer Potential of Genistein: Single-Cell RNA Sequencing Analysis and Spatial Transcriptome Reveal That Genistein Targets HSD17B1 to Inhibit the Progression of Gastric Adenocarcinoma.International journal of molecular sciences · 2025Article
- Identification and validation of tumor microenvironment-related therapeutic targets in gastric cancer using integrated multi-omics and molecular docking approaches.Frontiers in bioinformatics · 2025Article
- FAT4 Mutation is Related to Tumor Mutation Burden and Favorable Prognosis in Gastric Cancer.Current genomics · 2024Article
- Clinically conserved genomic subtypes of gastric adenocarcinoma.Molecular cancer · 2023Article
- Role of CD14 in human disease.Immunology · 2023Review
- The Comprehensive Analysis of N6-Methyadenosine Writer METTL3 and METTL14 in Gastric Cancer.Journal of oncology · 2023Article
- Role of spasmolytic polypeptide-expressing metaplasia in gastric mucosal diseases.American journal of cancer research · 2023Review
- Systematic Review and Meta-analysis of TP53, HER2/ERBB2, KRAS, APC, and PIK3CA Genes Expression Pattern in Gastric Cancer.Middle East journal of digestive diseases · 2022Review
- The dawn of precision medicine in diffuse-type gastric cancer.Therapeutic advances in medical oncology · 2022Review
- Transcriptome profiling analysis of the response to walnut polyphenol extract inJournal of clinical biochemistry and nutrition · 2021Article
- Clinical difference between fibroblast growth factor receptor 2 subclass, type IIIb and type IIIc, in gastric cancer.Scientific reports · 2021Article
- The Tumor Microenvironment in SCC: Mechanisms and Therapeutic Opportunities.Frontiers in cell and developmental biology · 2021Review
- Identification of Hub Genes and Pathways in Gastric Adenocarcinoma Based on Bioinformatics Analysis.Medical science monitor : international medical journal of experimental and clinical research · 2020Article
- Bayesian differential analysis of gene regulatory networks exploiting genetic perturbations.BMC bioinformatics · 2020Article
- Inference of differential gene regulatory networks based on gene expression and genetic perturbation data.Bioinformatics (Oxford, England) · 2020Article
- The role of hedgehog signaling in gastric cancer: molecular mechanisms, clinical potential, and perspective.Cell communication and signaling : CCS · 2019Review
- Targeted genomic profiling identifies frequent deleterious mutations in FAT4 and TP53 genes in HBV-associated hepatocellular carcinoma.BMC cancer · 2019Article
- Five-long non-coding RNA risk score system for the effective prediction of gastric cancer patient survival.Oncology letters · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGlobally, gastric cancer is the second most common cause of cancer-related death, with the majority of the health burden borne by economically less-developed countries.
methodsHere, we report a genetic characterization of 50 gastric adenocarcinoma samples, using affymetrix SNP arrays and Illumina mRNA expression arrays as well as Illumina sequencing of the coding regions of 384 genes belonging to various pathways known to be altered in other cancers.
resultsGenetic alterations were observed in the WNT, Hedgehog, cell cycle, DNA damage and epithelial-to-mesenchymal-transition pathways.
conclusionsThe data suggests targeted therapies approved or in clinical development for gastric carcinoma would be of benefit to ~22% of the patients studied. In addition, the novel mutations detected here, are likely to influence clinical response and suggest new targets for drug discovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.